Advanced search

Platinum-based chemotherapy plus cetuximab in head and neck cancer

(2008) New England Journal of Medicine. 359(11). p.1116-1127
Author
Organization
Abstract
Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. Methods: We randomly assigned 220 of 442 eligible patients with untreated recurrent or metastatic squamous-cell carcinoma of the head and neck to receive cisplatin (at a dose of 100 mg per square meter of body-surface area on day 1) or carboplatin (at an area under the curve of 5 mg per milliliter per minute, as a 1-hour intravenous infusion on day 1) plus fluorouracil (at a dose of 1000 mg per square meter per day for 4 days) every 3 weeks for a maximum of 6 cycles and 222 patients to receive the same chemotherapy plus cetuximab (at a dose of 400 mg per square meter initially, as a 2-hour intravenous infusion, then 250 mg per square meter, as a 1-hour intravenous infusion per week) for a maximum of 6 cycles. Patients with stable disease who received chemotherapy plus cetuximab continued to receive cetuximab until disease progression or unacceptable toxic effects, whichever occurred first. Results: Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracil) significantly prolonged the median overall survival from 7.4 months in the chemotherapy-alone group to 10.1 months in the group that received chemotherapy plus cetuximab (hazard ratio for death, 0.80; 95% confidence interval, 0.64 to 0.99; P=0.04). The addition of cetuximab prolonged the median progression-free survival time from 3.3 to 5.6 months (hazard ratio for progression, 0.54; P<0.001) and increased the response rate from 20% to 36% (P<0.001). The most common grade 3 or 4 adverse events in the chemotherapy-alone and cetuximab groups were anemia (19% and 13%, respectively), neutropenia (23% and 22%), and thrombocytopenia (11% in both groups). Sepsis occurred in 9 patients in the cetuximab group and in 1 patient in the chemotherapy-alone group (P=0.02). Of 219 patients receiving cetuximab, 9% had grade 3 skin reactions and 3% had grade 3 or 4 infusion-related reactions. There were no cetuximab-related deaths. Conclusions: As compared with platinum-based chemotherapy plus fluorouracil alone, cetuximab plus platinum-fluorouracil chemotherapy improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck.
Keywords
SINGLE-AGENT, RECURRENT, CISPLATIN, COPY NUMBER, ONCOLOGY-GROUP, ANTIBODY CETUXIMAB, PHASE-II MULTICENTER, SQUAMOUS-CELL CARCINOMA, GROWTH-FACTOR RECEPTOR, FLUOROURACIL

Citation

Please use this url to cite or link to this publication:

Chicago
Vermorken, Jan, Ricard Mesia, Fernando Rivera, Eva Remenar, Andrzej Kawecki, Sylvie Rottey, Jozsef Erfan, et al. 2008. “Platinum-based Chemotherapy Plus Cetuximab in Head and Neck Cancer.” New England Journal of Medicine 359 (11): 1116–1127.
APA
Vermorken, Jan, Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., et al. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. New England Journal of Medicine, 359(11), 1116–1127.
Vancouver
1.
Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New England Journal of Medicine. Waltham, MA USA: Massachusetts Medical Soc; 2008;359(11):1116–27.
MLA
Vermorken, Jan, Ricard Mesia, Fernando Rivera, et al. “Platinum-based Chemotherapy Plus Cetuximab in Head and Neck Cancer.” New England Journal of Medicine 359.11 (2008): 1116–1127. Print.
@article{602446,
  abstract     = {Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck.
Methods: We randomly assigned 220 of 442 eligible patients with untreated recurrent or metastatic squamous-cell carcinoma of the head and neck to receive cisplatin (at a dose of 100 mg per square meter of body-surface area on day 1) or carboplatin (at an area under the curve of 5 mg per milliliter per minute, as a 1-hour intravenous infusion on day 1) plus fluorouracil (at a dose of 1000 mg per square meter per day for 4 days) every 3 weeks for a maximum of 6 cycles and 222 patients to receive the same chemotherapy plus cetuximab (at a dose of 400 mg per square meter initially, as a 2-hour intravenous infusion, then 250 mg per square meter, as a 1-hour intravenous infusion per week) for a maximum of 6 cycles. Patients with stable disease who received chemotherapy plus cetuximab continued to receive cetuximab until disease progression or unacceptable toxic effects, whichever occurred first.

Results: Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracil) significantly prolonged the median overall survival from 7.4 months in the chemotherapy-alone group to 10.1 months in the group that received chemotherapy plus cetuximab (hazard ratio for death, 0.80; 95\% confidence interval, 0.64 to 0.99; P=0.04). The addition of cetuximab prolonged the median progression-free survival time from 3.3 to 5.6 months (hazard ratio for progression, 0.54; P{\textlangle}0.001) and increased the response rate from 20\% to 36\% (P{\textlangle}0.001). The most common grade 3 or 4 adverse events in the chemotherapy-alone and cetuximab groups were anemia (19\% and 13\%, respectively), neutropenia (23\% and 22\%), and thrombocytopenia (11\% in both groups). Sepsis occurred in 9 patients in the cetuximab group and in 1 patient in the chemotherapy-alone group (P=0.02). Of 219 patients receiving cetuximab, 9\% had grade 3 skin reactions and 3\% had grade 3 or 4 infusion-related reactions. There were no cetuximab-related deaths.

Conclusions: As compared with platinum-based chemotherapy plus fluorouracil alone, cetuximab plus platinum-fluorouracil chemotherapy improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck.},
  author       = {Vermorken, Jan and Mesia, Ricard and Rivera, Fernando and Remenar, Eva and Kawecki, Andrzej and Rottey, Sylvie and Erfan, Jozsef and Zabolotnyy, Dmytro and Kienzer, Heinz-Roland and Cupissol, Didier and Peyrade, Frederic and Benasso, Marco and Vynnychenko, Ihor and De Raucourt, Dominique and Bokemeyer, Carsten and Schueler, Armin and Amellal, Nadia and Hitt, Ricardo},
  issn         = {0028-4793},
  journal      = {New England Journal of Medicine},
  language     = {eng},
  number       = {11},
  pages        = {1116--1127},
  publisher    = {Massachusetts Medical Soc},
  title        = {Platinum-based chemotherapy plus cetuximab in head and neck cancer},
  volume       = {359},
  year         = {2008},
}

Web of Science
Times cited: